Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 6623 Download: 247 Web of Science: 4 Crossref: 5

Epidemiology of metabolic dysfunction-associated steatotic liver disease

Zobair M. Younossi, Markos Kalligeros, Linda Henry

Clin Mol Hepatol. 2025;31(Suppl):S32-S50. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0431

View: 17217 Download: 2,071 Web of Science: 76 Crossref: 71

Research Letter

Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e268-e272. Published online May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0384

View: 533 Download: 34

Correspondence

The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e183-e185. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0152

View: 876 Download: 16 Crossref: 1

Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e180-e182. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0125

View: 863 Download: 24

Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(2):e173-e175. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2025.0001

View: 951 Download: 30 Web of Science: 1 Crossref: 1

Letter to the Editor

MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song

Clin Mol Hepatol. 2025;31(2):e128-e133. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1008

View: 1550 Download: 79 Web of Science: 2 Crossref: 2

Original Article

Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation

Ester Ciociola, Tanmoy Dutta, Kavitha Sasidharan, Lohitesh Kovooru, Francesca R. Noto, Grazia Pennisi, Salvatore Petta, Angela Mirarchi, Samantha Maurotti, Bernardette Scopacasa, Luca Tirinato, Patrizio Candeloro, Marcus Henricsson, Daniel Lindén, Oveis Jamialahmadi, Arturo Pujia, Rosellina M. Mancina, Stefano Romeo

Clin Mol Hepatol. 2025;31(2):445-459. Published online December 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0642

View: 3035 Download: 367 Web of Science: 2 Crossref: 3

Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):382-393. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987

View: 3956 Download: 485 Web of Science: 11 Crossref: 16

Correspondence

Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Yuri Cho, Dae Won Jun

Clin Mol Hepatol. 2025;31(1):e103-e104. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0818

View: 1148 Download: 41

Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Clin Mol Hepatol. 2025;31(1):e70-e73. Published online September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0761

View: 1242 Download: 64

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(1):e64-e66. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0638

View: 1347 Download: 53 Web of Science: 1 Crossref: 1

Snapshot

Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues

Clara Meda, Arianna Dolce, Sara Della Torre

Clin Mol Hepatol. 2025;31(1):327-332. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0419

View: 1629 Download: 92 Crossref: 1

Editorial

A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Johanna K. DiStefano, Glenn S. Gerhard

Clin Mol Hepatol. 2025;31(1):297-300. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0704

View: 1182 Download: 33 Crossref: 1

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Andrea Caddeo, Rosellina M. Mancina

Clin Mol Hepatol. 2025;31(1):293-296. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0703

View: 1690 Download: 111 Crossref: 3

Original Article

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Clin Mol Hepatol. 2025;31(1):179-195. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0359

View: 2103 Download: 168 Web of Science: 2 Crossref: 2

Review

Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations

Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim

Clin Mol Hepatol. 2025;31(1):74-89. Published online October 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0631

View: 4654 Download: 398 Web of Science: 11 Crossref: 15

Reply to Correspondence

Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(4):1033-1034. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0360

View: 1581 Download: 31

Letter to the Editor

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0691

View: 2018 Download: 67 Web of Science: 1 Crossref: 1

Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau

Clin Mol Hepatol. 2024;30(4):978-981. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0565

View: 1704 Download: 58 Web of Science: 1 Crossref: 2

Original Article

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan

Chung-Feng Huang, Chia-Yen Dai, Yi-Hung Lin, Chih-Wen Wang, Tyng-Yuan Jang, Po-Cheng Liang, Tzu-Chun Lin, Pei-Chien Tsai, Yu-Ju Wei, Ming-Lun Yeh, Ming-Yen Hsieh, Chao-Kuan Huang, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(4):883-894. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0414

View: 2704 Download: 141 Web of Science: 7 Crossref: 3

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium

Clin Mol Hepatol. 2024;30(4):824-844. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0229

View: 3530 Download: 333 Web of Science: 4 Crossref: 3

Correspondence

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”

Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):287-290. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0136

View: 3093 Download: 79 Crossref: 1

Original Article

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression

Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):247-262. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0449

View: 6578 Download: 315 Web of Science: 11 Crossref: 10

Editorial

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

Carlos Jose Pirola, Silvia Sookoian

Clin Mol Hepatol. 2024;30(2):174-176. Published online February 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0082

View: 3370 Download: 87 Web of Science: 2 Crossref: 2

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2024;30(2):168-170. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0140

View: 3560 Download: 102 Web of Science: 6 Crossref: 7

Adding to the confusion in more than just the name

Jacob George

Clin Mol Hepatol. 2023;29(4):973-976. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0367

View: 2998 Download: 89 Web of Science: 6 Crossref: 7

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359

View: 4128 Download: 189 Web of Science: 11 Crossref: 13

Review

Prospects of Mendelian Randomization in Hepatology: A Comprehensive Literature Review with Practice Guidance Mendelian randomization and hepatology

Lanlan Chen, Qi Rao, Menghan Gao, Guoyue Lv, Frank Tacke

Received May 16, 2025 Accepted June 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0541 [Accepted]

View: 775 Download: 86

1 |

Viewed By 12461	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7606	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7052	MAFLD: How is it different from NAFLD?
Viewed By 5653	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5516	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search